UCB SA (UCBJY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jean-Christophe Tellier | CEO & Executive Director | 4.37M | -- | 1959 |
| Ms. Sandrine Dufour CFA | Executive VP, CFO & Chief Corporate Development | -- | -- | 1966 |
| Dr. Kirsten Lund-Jurgensen Ph.D. | Executive Vice President of Supply & Technology Solutions | -- | -- | 1960 |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive VP & Chief Scientific Officer | -- | -- | 1961 |
| Ms. Denelle J. Waynick Johnson J.D. | Executive VP & General Counsel | -- | -- | 1967 |
| Mr. Jean-Luc Fleurial | Executive VP & Chief Human Resources Officer | -- | -- | 1965 |
| Prof. Iris Low-Friedrich | Executive VP & Chief Medical Officer | -- | -- | 1960 |
| Mr. Emmanuel Caeymaex | Executive VP of Immunology Solutions & Head of US | -- | -- | 1969 |
| Ms. Caroline Vancoillie | Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions | -- | -- | -- |
| Antje Witte | Head of Investor Relations | -- | -- | -- |
UCB SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8,450
Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Corporate Governance
Recent Events
- May 18, 2023Dividend Date
- May 01, 2023Ex-Dividend Date
Upcoming Events
Upcoming Events Information Not Available